Movatterモバイル変換


[0]ホーム

URL:


IL143670A0 - Methods for the expression of active protein-immunoglobulin fusions, active protein-immunoglobulin fusions obtained thereby and pharmaceutical compositions containing the same - Google Patents

Methods for the expression of active protein-immunoglobulin fusions, active protein-immunoglobulin fusions obtained thereby and pharmaceutical compositions containing the same

Info

Publication number
IL143670A0
IL143670A0IL14367099AIL14367099AIL143670A0IL 143670 A0IL143670 A0IL 143670A0IL 14367099 AIL14367099 AIL 14367099AIL 14367099 AIL14367099 AIL 14367099AIL 143670 A0IL143670 A0IL 143670A0
Authority
IL
Israel
Prior art keywords
active protein
immunoglobulin fusions
methods
expression
pharmaceutical compositions
Prior art date
Application number
IL14367099A
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filedlitigationCriticalhttps://patents.darts-ip.com/?family=22345666&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL143670(A0)"Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen IncfiledCriticalBiogen Inc
Publication of IL143670A0publicationCriticalpatent/IL143670A0/en

Links

Classifications

Landscapes

Abstract

Methods for high level expression of active lymphotoxin-² receptor immunoglogulin chimeric proteins and their purification.
IL14367099A1998-12-171999-12-16Methods for the expression of active protein-immunoglobulin fusions, active protein-immunoglobulin fusions obtained thereby and pharmaceutical compositions containing the sameIL143670A0 (en)

Applications Claiming Priority (2)

Application NumberPriority DateFiling DateTitle
US11275298P1998-12-171998-12-17
PCT/US1999/029873WO2000036092A2 (en)1998-12-171999-12-16METHOD FOR THE HIGH LEVEL EXPRESSION OF ACTIVE LYMPHOTOXIN-β RECEPTOR IMMUNOGLOBULIN CHIMERIC PROTEINS AND THEIR PURIFICATION

Publications (1)

Publication NumberPublication Date
IL143670A0true IL143670A0 (en)2002-04-21

Family

ID=22345666

Family Applications (3)

Application NumberTitlePriority DateFiling Date
IL14367099AIL143670A0 (en)1998-12-171999-12-16Methods for the expression of active protein-immunoglobulin fusions, active protein-immunoglobulin fusions obtained thereby and pharmaceutical compositions containing the same
IL205698AIL205698A (en)1998-12-172010-05-11Methods for increasing expression of active tumor necrosis factor (tnf) receptor family member - ig fc fusion proteins and minimizing expression of inactive tnf receptor family member ig fc fusion proteins
IL229738AIL229738A0 (en)1998-12-172013-12-01Methods and compositions for increasing expression of active tumor necrosis factor (tnf)receptor family member-lg fc fusion proteins

Family Applications After (2)

Application NumberTitlePriority DateFiling Date
IL205698AIL205698A (en)1998-12-172010-05-11Methods for increasing expression of active tumor necrosis factor (tnf) receptor family member - ig fc fusion proteins and minimizing expression of inactive tnf receptor family member ig fc fusion proteins
IL229738AIL229738A0 (en)1998-12-172013-12-01Methods and compositions for increasing expression of active tumor necrosis factor (tnf)receptor family member-lg fc fusion proteins

Country Status (27)

CountryLink
US (3)US7585946B2 (en)
EP (3)EP2374872B2 (en)
JP (4)JP4878676B2 (en)
KR (3)KR20020013482A (en)
CN (2)CN100387708C (en)
AT (1)ATE536372T1 (en)
AU (2)AU777232B2 (en)
BR (1)BR9916325B1 (en)
CA (1)CA2354539A1 (en)
CY (1)CY1117003T1 (en)
CZ (1)CZ20012156A3 (en)
DK (2)DK2374872T4 (en)
EA (1)EA005270B1 (en)
EE (1)EE200100324A (en)
ES (1)ES2554482T5 (en)
HK (1)HK1223398A1 (en)
HU (1)HUP0200064A2 (en)
IL (3)IL143670A0 (en)
IS (1)IS5959A (en)
NO (1)NO20012991L (en)
NZ (3)NZ529276A (en)
PT (1)PT2374872E (en)
SG (1)SG123531A1 (en)
SI (1)SI2374872T2 (en)
SK (1)SK8552001A3 (en)
TR (2)TR200504220T2 (en)
WO (1)WO2000036092A2 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US5925351A (en)*1995-07-211999-07-20Biogen, Inc.Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US7060667B1 (en)1998-01-302006-06-13Biogen Idec Ma, Inc.Treatment of follicular lymphomas using inhibitors of the LT pathway
TR200100974T2 (en)*1998-10-092001-11-21Biogen, Inc. Systematic shock and respiratory distress caused by virus rejection by blocking the lymphotoxin beta pathway
AU2001257445B2 (en)2000-04-282006-11-02Planet Biotechnology, Inc.Immunoadhesin for the prevention of rhinovirus infection
US20020168367A1 (en)*2000-04-282002-11-14Planet Biotechnology IncorporatedNovel immunoadhesins for treating and preventing viral and bacterial diseases
US20090137416A1 (en)2001-01-162009-05-28Regeneron Pharmaceuticals, Inc.Isolating Cells Expressing Secreted Proteins
CA2434802C (en)*2001-01-162013-05-28Regeneron Pharmaceuticals, Inc.Isolating cells expressing secreted proteins
JP2006515750A (en)*2002-12-202006-06-08バイオジェン・アイデック・エムエイ・インコーポレイテッド Multivalent lymphotoxin β receptor agonist and treatment using the same
MXPA05006523A (en)2002-12-232005-08-26Squibb Bristol Myers CoMammalian cell culture processes for protein production.
TWI328614B (en)2002-12-232010-08-11Bristol Myers Squibb CoProduct quality enhancement in mammalian cell culture processes for protein production
WO2005024012A1 (en)*2003-09-112005-03-17Novozymes A/SIncreased expression of a modified polypeptide
US20070099266A1 (en)*2003-12-232007-05-03Applied Research Systems Ars Holding N.V.Process for the production of tumor necrosis factor-binding proteins
US20110038854A1 (en)*2006-03-302011-02-17University Of Medicine And Dentistry Of New JerseyStrategy for homo- or hetero-dimerization of various proteins in solution and in cell
EP2084188A2 (en)*2006-10-122009-08-05Genentech, Inc.Antibodies to lymphotoxin-alpha
EP2311481A3 (en)*2006-10-202013-10-16Biogen Idec MA Inc.Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor
US8338376B2 (en)2006-10-202012-12-25Biogen Idec Ma Inc.Compositions comprising variant LT-B-R-IG fusion proteins
CA2680792A1 (en)*2007-03-152008-09-18Biogen Idec Ma Inc.Treatment of autoimmune disorders
TW200902708A (en)2007-04-232009-01-16Wyeth CorpMethods of protein production using anti-senescence compounds
BRPI0908270A2 (en)*2008-02-292019-09-10Biogen Idec Inc purified immunoglobulin fusion proteins and method for their purification
US9540426B2 (en)2009-10-062017-01-10Bristol-Myers Squibb CompanyMammalian cell culture processes for protein production
LT2563906T (en)2010-04-262018-02-26Novartis AgProcess for cultivation of cho cells
WO2012176158A1 (en)*2011-06-242012-12-27Dr. Reddy's Laboratories LimitedPurification of chimeric protein
EP2753634B1 (en)2011-08-172017-11-01Ares Trading S.A.Method for preparing active form of tnfr-fc fusion protein
ES2633960T3 (en)2012-10-152017-09-26Bristol-Myers Squibb Company Processes of mammalian cell culture for protein production
TWI864338B (en)2012-11-142024-12-01美商再生元醫藥公司Recombinant cell surface capture proteins
IL297395B2 (en)2015-06-302024-01-01PfizerBtla fusion protein agonists and uses thereof
KR101936049B1 (en)2015-10-152019-01-08(주)알테오젠Method for manufacturing fusion proteins with IgG Fc domain
CN105400721A (en)*2015-12-112016-03-16湖南农业大学Method for rapid screening of Bacillus spp with antibacterial activity

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US2906096A (en)1953-12-141959-09-29Pacific Ind Mfg CoPrecision control system for press brakes or the like
EP0480923B1 (en)1989-07-041993-09-29Novo Nordisk A/SMethod of producing proteins with fviii activity and/or fviii derivatives
US5605690A (en)*1989-09-051997-02-25Immunex CorporationMethods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
WO1992000329A1 (en)1990-06-271992-01-09Biogen, Inc.Surface complexed lymphotoxin
US7030080B2 (en)1990-06-272006-04-18Biogen, Inc.Lymphotoxin-β, lymphotoxin-β complexes, pharmaceutical preparations and therapeutic uses thereof
US5795964A (en)1990-06-271998-08-18Biogen, Inc.Lymphotoxin-beta and lymphotoxin-beta complexes
WO1992020791A1 (en)1990-07-101992-11-26Cambridge Antibody Technology LimitedMethods for producing members of specific binding pairs
NZ260103A (en)*1990-11-301996-10-28Bio Technology General CorpSomatotropin with alterations in the alpha-helix-1 region
US5656272A (en)1991-03-181997-08-12New York University Medical CenterMethods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
IE922437A1 (en)1991-07-251993-01-27Idec Pharma CorpRecombinant antibodies for human therapy
US5447851B1 (en)*1992-04-021999-07-06Univ Texas System Board OfDna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
US5643570A (en)*1992-05-191997-07-01Xoma CorporationBPI-immunoglobulin fusion proteins
WO1994006476A1 (en)*1992-09-151994-03-31Immunex CorporationMethod of treating tnf-dependent inflammation using tumor necrosis factor antagonists
WO1994006478A1 (en)1992-09-221994-03-31Medin CorporationA system for securing medical tools for sterilization
AU690528B2 (en)1992-12-041998-04-30Medical Research CouncilMultivalent and multispecific binding proteins, their manufacture and use
US5691196A (en)*1992-12-311997-11-25American Cyanamid CompanyRecombinant nucleic acid containing a response element
US5429746A (en)*1994-02-221995-07-04Smith Kline Beecham CorporationAntibody purification
US5856179A (en)1994-03-101999-01-05Genentech, Inc.Polypeptide production in animal cell culture
US5726039A (en)1994-07-211998-03-10Yissum Research Development Co. Of The Hebrew University Of JerusalemVectors and transformed host cells for recombinant protein production at reduced temperatures
US5541087A (en)1994-09-141996-07-30Fuji Immunopharmaceuticals CorporationExpression and export technology of proteins as immunofusins
US6312691B1 (en)1996-01-262001-11-06Jeffrey L. BrowningLymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US5705364A (en)*1995-06-061998-01-06Genentech, Inc.Mammalian cell culture process
US5721121A (en)*1995-06-061998-02-24Genentech, Inc.Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
US5925351A (en)1995-07-211999-07-20Biogen, Inc.Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US6291207B1 (en)*1995-07-282001-09-18Northwestern UniversityHerpes virus entry receptor protein
JP4306813B2 (en)1995-09-192009-08-05アスビオファーマ株式会社 New method for culturing animal cells
EP0910413A2 (en)*1996-05-081999-04-28F. Hoffmann-La Roche AgTREATMENT OF ASTHMA WITH TNFR-Ig
US6040560A (en)*1996-10-222000-03-21Philip Morris IncorporatedPower controller and method of operating an electrical smoking system
US7255854B1 (en)1996-10-252007-08-14Biogen, Inc.Use of lymphotoxin-β receptor blocking agents for the treatment of antibody mediated immunological diseases
CN100382844C (en)1996-10-252008-04-23拜奥根Idec马萨诸塞公司Soluble beta-lymphotoxin receptor and anti-lymphotoxin receptor antibodies and uses of anti-lymphotoxin ligand antibodies
WO1998018824A1 (en)*1996-10-301998-05-07Human Genome Sciences, Inc.Human tumor necrosis factor receptor-like 2
CA2272822A1 (en)*1996-12-121998-06-18Genentech, Inc.Hvem polypeptides and uses thereof
US6221608B1 (en)*1997-01-222001-04-24Ortho Pharmaceutical CorporationMethods for identifying erythropoietin receptor binding protein
US7060667B1 (en)1998-01-302006-06-13Biogen Idec Ma, Inc.Treatment of follicular lymphomas using inhibitors of the LT pathway
AU763513B2 (en)*1998-04-162003-07-24Genentech Inc.Secretion of glycosylated proteins using a tissue plasminogen activator pro-sequence
DE69929198T2 (en)1998-05-292006-08-10Genentech, Inc., South San Francisco CELL CULTURE PROCESS FOR THE PRODUCTION OF GLYCOPROTEINS
TR200100974T2 (en)*1998-10-092001-11-21Biogen, Inc. Systematic shock and respiratory distress caused by virus rejection by blocking the lymphotoxin beta pathway
US7294481B1 (en)1999-01-052007-11-13Immunex CorporationMethod for producing recombinant proteins
US9086881B2 (en)2012-06-292015-07-21Intel CorporationMechanism for facilitating write tracking for following data eye movements across changing thermal conditions in memory systems

Also Published As

Publication numberPublication date
WO2000036092A3 (en)2000-11-23
JP4878676B2 (en)2012-02-15
BR9916325A (en)2001-10-02
NZ529276A (en)2005-03-24
NZ538599A (en)2007-11-30
KR100732934B1 (en)2007-06-29
AU777232B2 (en)2004-10-07
AU2364400A (en)2000-07-03
AU2005200042A1 (en)2005-02-03
AU2005200042B2 (en)2008-05-01
JP2010158252A (en)2010-07-22
SG123531A1 (en)2006-07-26
JP2013116118A (en)2013-06-13
EP2374872B2 (en)2019-02-20
US20020039580A1 (en)2002-04-04
IL205698A (en)2015-11-30
HK1223398A1 (en)2017-07-28
CN100387708C (en)2008-05-14
NZ549623A (en)2008-05-30
JP5777171B2 (en)2015-09-09
DK2374872T3 (en)2015-12-14
US7585946B2 (en)2009-09-08
WO2000036092A9 (en)2002-08-22
EP2374872A3 (en)2011-10-19
EE200100324A (en)2002-10-15
KR20060084860A (en)2006-07-25
CZ20012156A3 (en)2001-09-12
CN1333819A (en)2002-01-30
EA200100670A1 (en)2001-12-24
US20130196376A1 (en)2013-08-01
ES2554482T5 (en)2019-07-18
PT2374872E (en)2015-12-09
EP2374872A2 (en)2011-10-12
TR200101703T2 (en)2002-05-21
DK1141248T3 (en)2012-03-12
ATE536372T1 (en)2011-12-15
DK2374872T4 (en)2019-04-23
BR9916325B1 (en)2011-06-28
CY1117003T1 (en)2017-04-05
US8709759B2 (en)2014-04-29
CA2354539A1 (en)2000-06-22
JP2014239697A (en)2014-12-25
EP1141248B1 (en)2011-12-07
CN101289512A (en)2008-10-22
KR20070091227A (en)2007-09-07
NO20012991D0 (en)2001-06-15
US8283138B2 (en)2012-10-09
SI2374872T2 (en)2019-05-31
NO20012991L (en)2001-08-17
SI2374872T1 (en)2016-03-31
HK1038244A1 (en)2002-03-08
HUP0200064A2 (en)2002-05-29
EA005270B1 (en)2004-12-30
IL229738A0 (en)2014-01-30
EP2374872B1 (en)2015-11-25
WO2000036092A2 (en)2000-06-22
EP1141248A2 (en)2001-10-10
SK8552001A3 (en)2001-12-03
IS5959A (en)2001-05-31
ES2554482T3 (en)2015-12-21
KR20020013482A (en)2002-02-20
PL348816A1 (en)2002-06-17
US20100136625A1 (en)2010-06-03
JP2003517277A (en)2003-05-27
TR200504220T2 (en)2007-04-24
EP3006563A1 (en)2016-04-13

Similar Documents

PublicationPublication DateTitle
IL143670A0 (en)Methods for the expression of active protein-immunoglobulin fusions, active protein-immunoglobulin fusions obtained thereby and pharmaceutical compositions containing the same
IL185142A0 (en)Lentiviral packaging constructs
IL130190A0 (en)Methods and compositions for polypeptide engineering
IL132067A0 (en)Apo-2 receptor
BG105028A (en)Bridged indenopyrrolocarbazoles
TR200000152T2 (en) New compounds.
NZ330837A (en)Fused pyrrolo(2,3-c)carbazole-6-ones which potentiate activity of gamma interferon
NO992916L (en) Phosphodiesterase 8A
MXPA01003868A (en)Apomixis conferred by expression of serk interacting proteins.
EP0990703A4 (en)Novel polypeptide, dna encoding the same and use thereof
IL128500A (en)SUBSTITUTED 1,2,3,4-TETRAHYDRO-2-DIBENZOFURANAMINES AND 2-AMINOCYCLOHEPTA[b] BENZOFURANS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
MY127474A (en)Naphthyl compounds, intermediates, compositions, and methods of use
BR9713176A (en) Amorphous benzothiophenes, methods of preparation and methods of use
EE04944B1 (en) Bacterial plasmids for use as expression vectors or for microbiological analysis
YU26001A (en)Ureidopiperidine derivatives as selective human nk3 receptor antagonists
EP0778833A4 (en)Endothelin receptor antagonists
ID27656A (en) AZABISIKLOHEPTANA N-SUBSTITUTIONAL DERIVES, THE PRODUCTION AND USE OF IT
IL148234A0 (en)Composition for ivf
ES2051953T3 (en) ISOMEROUS DERIVATIVES OF TRIMETILBICICLO (4,3,0) NONANO.
AU1801699A (en)Creation of heteroimmunity amongst ctx$g(f): methods and compounds for the construction of improved (v. cholerae) vaccines
ID27964A (en) TURUNA-AZABISIKLOHEPTANA N-SUBSTITUTED, MAKING AND USING IT
MY127539A (en)Bridged indenopyrrolocarbazoles
MX9804706A (en)Fused isoindolones as inhibitors of protein kinase c.
UA30553C2 (en) Vodka SPECIAL "UNION"
ECSP961901A (en) IMIDAZOLIDIN COMPOUNDS 2,4- DIONA SUBSTITUTED

[8]ページ先頭

©2009-2025 Movatter.jp